A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.
Chemotherapy Induced Anemia
DRUG: recombinant human erythropoietin|DRUG: recombinant human erythropoietin
The increase in Hb concentration, Day 28th or later
Changes in QOL scores, 84 days
The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.